Publication | Closed Access

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

Urological ResearchUrologyVoiding DysfunctionMedicinePhase IiiPharmacotherapyPain ManagementUrogynecologyβ3 Adrenoceptor AgonistPharmacologyOveractive Bladder